Home › Funds › Alessandra Capital Management, LLC › BIOA
Alessandra Capital Management, LLC position in BIOA
BioAge Labs Inc · Health Care
Alessandra Capital Management, LLC reported holding 93,368 shares of BIOA (BioAge Labs Inc) in its Q2 2026 13F filing — a position valued at US$2.3M, representing 1.62% of its reported portfolio and ranking #15 among its reported holdings. Alessandra Capital Management, LLC has disclosed BIOA holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Alessandra Capital Management, LLC's BIOA position evolved
Alessandra Capital Management, LLC first disclosed a stake in BIOA in Q4 2025 at 135,660 shares (US$1.8M). The position peaked in Q2 2026 at 93,368 shares, worth US$2.3M. Across 3 filings, Alessandra Capital Management, LLC increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 93,368 shares valued at US$2.3M — a reduction of -14,452 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 135.66K | $1.79M | New |
| Q1 2026 | 107.82K | $1.89M | Reduce |
| Q2 2026 | 93.37K | $2.29M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BIOA and 13F data
BIOA (BioAge Labs Inc) is a Health Care company. 79 other funds we track also report a position in BIOA — the largest reported positions include a16z Capital Management, L.L.C. (US$79.2M), Cormorant Asset Management, LP (US$58.6M), Sofinnova Investments, Inc. (US$56.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BIOA
- a16z Capital Management, L.L.C. 3.23M sh · $79.24M · Q2 2026
- Cormorant Asset Management, LP 2.39M sh · $58.59M · Q2 2026
- Sofinnova Investments, Inc. 2.29M sh · $56.22M · Q2 2026
- Octagon Capital Advisors LP 1.75M sh · $42.84M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 1.67M sh · $40.97M · Q2 2026
- MPM BioImpact LLC 1.67M sh · $40.87M · Q2 2026
- BRAIDWELL LP 1.03M sh · $25.32M · Q2 2026
- Sands Capital Alternatives, LLC 786.35K sh · $19.27M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 653.37K sh · $16.01M · Q2 2026
- Cosmic Management, LLC 501.83K sh · $12.30M · Q2 2026
- STEMPOINT CAPITAL LP 464.17K sh · $11.38M · Q2 2026
- Comprehensive Financial Management LLC 271.84K sh · $6.66M · Q2 2026
More on Alessandra Capital Management, LLC
FAQ
How long has Alessandra Capital Management, LLC held BIOA?
Alessandra Capital Management, LLC has disclosed BIOA holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Alessandra Capital Management, LLC's current position in BIOA?
As of Q2 2026, Alessandra Capital Management, LLC holds 93.37K shares of BIOA (BioAge Labs Inc), valued at $2.29M, representing 1.62% of its reported portfolio and ranking #15.
Has Alessandra Capital Management, LLC been buying or selling BIOA?
In the latest 13F filing (Q2 2026), Alessandra Capital Management, LLC reduced its position in BIOA. The position peaked in Q2 2026 at 93.37K shares.
Which other funds hold BIOA?
Other major institutional holders of BIOA include a16z Capital Management, L.L.C., Cormorant Asset Management, LP, Sofinnova Investments, Inc., among 79 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.